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ABSTRACT
Objective To explore the attitudes towards implantable 
cardioverter defibrillator (ICD) deactivation and initiation 
of deactivation discussions among patients, relatives and 
clinicians.
Design A multiphase qualitative study consisting of in 
situ hospital ICD clinic observations, and semistructured 
interviews of clinicians, patients and relatives. Data were 
analysed using a constant comparative approach.
Setting One tertiary and two district general hospitals in 
England.
Participants We completed 38 observations of 
hospital consultations prior to ICD implantation, and 80 
interviews with patients, family members and clinicians 
between 2013 and 2015. Patients were recruited from 
preimplantation to postdeactivation. Clinicians included 
cardiologists, cardiac physiologists, heart failure nurses 
and palliative care professionals.
Results Four key themes were identified from the data: 
the current status of deactivation discussions; patients’ 
perceptions of deactivation; who should take responsibility 
for deactivation discussions and decisions; and timing of 
deactivation discussions. We found that although patients 
and doctors recognised the importance of advance care 
planning, including ICD deactivation at an early stage in the 
patient journey, this was often not reflected in practice. The 
most appropriate clinician to take the lead was thought to be 
dependent on the context, but could include any appropriately 
trained member of the healthcare team. It was suggested that 
deactivation should be raised preimplantation and regularly 
reviewed. Identification of trigger points postimplantation 
for deactivation discussions may help ensure that these are 
timely and inappropriate shocks are avoided.
Conclusions There is a need for early, ongoing and 
evolving discussion between ICD recipients and clinicians 
regarding the eventual need for ICD deactivation. The most 
appropriate clinician to instigate deactivation discussions 
is likely to vary between patients and models of care. 
Reminders at key trigger points, and routine discussion 
of deactivation at implantation and during advance care 
planning could prevent distressing experiences for both 
the patient and their family at the end of life.
INTRODUCTION
Implantable cardioverter defibrillators (ICD) 
improve survival in patients at high risk of 
sudden cardiac death through delivering 
treatments to terminate life- threatening 
arrhythmia.1–3 However, as people age the risk of 
non- arrhythmic modes of death, such as frailty 
and accumulating comorbidity, progressive 
heart failure or other terminal diseases such as 
cancer may dominate, and the potential benefit 
from an ICD is reduced.4–6 More than one- third 
of hospitalised patients with an ICD experience 
a ventricular tachyarrhythmia within the last 
hour of life,7 and therefore leaving the device 
active is likely to lead to shocks at the end of life, 
which may be distressing, painful and futile.8–12 
Advance care planning (ACP) aims to ensure 
that appropriate measures are in place to aid 
patients’ transition to end- of- life care and ‘a 
good death’.13 Although guidelines suggest that 
ongoing ICD activation should be considered 
as part of a patient’s care goals,14 15 clinicians 
may be failing to engage patients sufficiently in 
ACP.9 16
Strengths and limitations of this study
 ► Implantable cardioverter defibrillator implants are 
increasing and existing recipients are ageing, which 
makes optimal end- of- life planning an important 
and topical issue.
 ► This is the first study of its kind to include both clinic 
observations and semistructured interviews.
 ► There was a robust recruitment strategy, with a 
large number of participants enrolled.
 ► However, this study lacks the perspectives of prima-
ry care clinicians.
 ► A limited number of patients who were actively con-
sidering deactivation was recruited.
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A proactive approach recommended by interna-
tional guidelines mandates deactivation discussion 
prior to implantation as a part of shared decision 
making.14 17 18 This has the declared support of both clini-
cians and patients.10 12 19 Yet there is evidence that this 
discussion does not routinely occur.20 21 Failure to engage 
patients may put undue pressure on family members to 
make deactivation decisions, who make more than half of 
deactivation requests.22 Previous work has identified that 
patients recall the positive, ‘life- saving’ attributes of ICD 
discussions more than pre- implant end- of- life ACP discus-
sions.23 24 In this study, we add to the existing evidence 
base by including non- participant observations in addi-
tion to semistructured interviews. The study provides a 
comprehensive exploration of patient, family member 
and clinician attitudes towards deactivation discussions. 




The study comprised two phases: clinical observations, 
and interviews with patients, family members and clini-
cians. All participants provided written informed consent, 
and the investigation conforms with the Declaration of 
Helsinki.25 Additional detail of the methods are provided 
in the full report.26
Patient and public involvement
Public and patient engagement was initiated prior to the 
development of the outline application, and their feed-
back guided the research question and study approach. 
The Founder and Trustee of Arrhythmia Alliance (TL) 
was a coapplicant and member of our study advisory 
group, and provided service user input into all stages, 
including coauthoring this manuscript and the report to 
the study funders. Two patient/carer representatives (with 
an interest in end- of- life issues) joined the initial project 
advisory group. The Arrhythmia Alliance and the North 
of England Cardiovascular Network reviewed the research 
proposal, and their comments were incorporated.
Sampling and recruitment
Phase 1: observations
Non- participant observations27 were conducted in clinics 
across three hospitals: one tertiary care (implanting) 
centre and two district general hospitals. Observations at 
the tertiary care centre were with two implanting cardiol-
ogists, and observations at district general hospitals were 
with two heart failure nurses and one non- implanting 
cardiologist. Observations allowed researchers (HS/KJ) 
to familiarise themselves with the clinical environment 
and decision- making about ICDs. Field notes informed 
the sampling strategy and interview schedules for phase 2.
Cardiologists identified patients attending to discuss 
ICD implantation. Opt- out consent was used for this 
phase; study information was mailed with appointment 
letters, explaining that a researcher might be present to 
observe their consultation. An opt- out slip was included, 
and patients were asked to present this on arrival if they 
chose not to participate.
Phase 2: interviews
Clinician interviews
Clinicians were recruited from five hospitals in the north 
of England with interviews, conducted over the tele-
phone or at the clinician’s place of work, exploring: the 
referral pathway for ICD implantation; approaches to 
risk communication; current approaches to, and people 
involved in, decision making; and timing of deactivation 
discussions. Purposive sampling28 was used to capture a 
range of perspectives from specialities involved in the 
care of ICD patients.
Patient and family member interviews
We sought to include a range of patient experiences from 
those considering ICD implantation to those recently 
deactivated, as well as bereaved family members of ICD 
recipients 4–18 months post bereavement. The inter-
view schedule covered issues identified through the 
observations and a literature review (see online supple-
mental material), including understandings of, and 
feelings about, the ICD; decision making about implan-
tation; whether, how and by whom deactivation had been 
discussed; and preferences for information and decision 
support.
Next- of- kin contact details for deceased patients with an 
ICD were identified and an information pack was mailed, 
including an introductory letter from the implanting 
cardiologist. The letter invited interested individuals to 
return a consent- to- contact form to the research team. 
When received, the researcher arranged an interview. 
Invitations offered the option of being interviewed with 
a friend or family member, or passing the invitation to 
someone more closely involved in the patient’s care. 
Interviews were conducted at the participants’ home or 
over the telephone and were audiorecorded, transcribed 
verbatim and anonymised.
Data analysis
Data collection was guided by the constant compara-
tive method.29 Data collection and analysis ran concur-
rently. Analysis of early interviews informed the interview 
schedule for subsequent interviews, and analysis was 
revised as data collection progressed. We critically exam-
ined the different perspectives and experiences of those 
involved in decision making about deactivation of ICDs. 
NVivo V.8 (QSR International, Warrington, UK) was used 
for data management. Data were analysed by three expe-
rienced qualitative researchers (HS and KJ, with support 
from CE). Regular meetings were held with the rest of the 
research team and the advisory group to discuss themes 
derived from the data. All names are pseudonyms.
Findings
Between July 2013 and January 2015, 38 observations of 
consultations led by heart failure nurses, non- implanting 
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and implanting cardiologists were conducted. Consulta-
tions lasted between 10 and 30 min. Forty- four patient 
interviews were conducted in 33 men and 11 women, 
aged between 47 and 85 years. Most patients (n=34) had 
been offered an ICD for primary prevention (patients 
without a history of sustained ventricular tachycardia or 
sudden cardiac arrest),18 the remainder (n=10) were for 
secondary prevention (with a history of sustained tachy-
cardia or sudden cardiac arrest).18
Table 1 provides a breakdown of patient, bereaved rela-
tive (n=7) and clinicians (n=29). Patient and bereaved 
relative interviews ranged from 11 to 113 (mean 44) min, 
clinician interviews from 20 to 83 (mean 42) min.
Four key themes were identified: the current status of 
deactivation discussions; patients’ perceptions of deac-
tivation; responsibility for deactivation discussions and 
decisions; and timing of deactivation discussions.
Current status of deactivation discussions
Clinicians recognised the importance of timely ICD 
deactivation to avoid patients experiencing unnecessary 
shocks towards the end of life; however, current manage-
ment of ICD deactivation was considered to be subop-
timal at times. Patients were not consistently engaged 
in deactivation discussions and when this did occur, the 
patient was often close to death. Failure to deactivate 
the ICD in a timely manner could result in stressful and 
upsetting situations.
I think the most recent one that we’ve had on the ward 
[…] the decision was left too late, the patient was getting 
shocked too frequently, and nobody had had the chat to 
the family to say, “Well this is the defibrillator doing all 
of this, distressing them, and what we can do about it”. 
(Dr J, non- implanting cardiologist) the patient in my 
view at that stage was actually dead, or was on the verge 
of being dead and it [ICD] was still delivering… Then 
once it had been deactivated, the patient passed away in 
a matter of a few moments. It wasn’t pleasant. (Nurse C, 
heart failure nurse)
Bereaved relatives felt that deactivation was often 
poorly handled. One suggested reason for this was clini-
cians’ apparent reticence to deactivate the ICD prior to 
the patient being in the last hours of life.
she [cardiologist] said his heart looked alright and 
she didn’t feel it was time to deactivate it … She [car-
diologist] said to me “Do you think that he’s ready to 
be deactivated?” And at the time I suppose I didn’t, 
I said no …So that wasn’t a very nice experience. 
(Shirley Bereaved wife)
Despite having engaged in ACP with a heart failure nurse, 
the patient’s preference for deactivation was questioned by 
the implanting cardiologist who deferred the decision to 
the patient’s wife. Although the ICD was eventually deacti-
vated, it was reported that this occurred only hours before 
death, following intervention by the heart failure nurse. The 
patient’s daughter, who also participated in the interview, 
felt it had been inappropriate for the cardiologist to put her 
mother in a position where she was expected to make an 
immediate deactivation decision.
Some patients reported facing apparent resistance 
from clinicians when trying to express their preference 
for deactivation.
What he [the cardiologist] actually said [was], ‘well, 
you’ll basically drop down dead as soon as I switch it 
off’. It was so unkind. I wouldn’t dare say that to any-
one. (Fred, ICD deactivated)
This reported response from the cardiologist caused 
the patient and his wife a great deal of distress, and 
misrepresented the function of the ICD. The cardiol-
ogist’s actions were perceived as an attempt to mislead 
the patient regarding the outcome of deactivation, so he 
would reconsider his decision to decline further medical 
intervention. This patient had declined his cardiolo-
gist’s recommendation to be placed on the waiting list 
for heart transplant owing to previous experiences with 
organ transplantation and the associated side effects; 
the patient accepted he was approaching end of life and 
wanted limited intervention. Rather than exploring the 
patient’s reasons for requesting deactivation, this account 
would seem to demonstrate a failure to undertake Shared 
Decision Making (SDM).









Bereaved spouse and daughter 2




Non- implanting cardiologist 5
Arrhythmia nurse 1
Heart failure nurses (hospital and community) 6
Cardiac physiologists* 4
Health psychologists 2
Palliative care specialists 6
Total 29
Overall total 80
*A cardiac physiologist is a clinical scientist, known as a device 
(ICD or pacemaker) technician in the USA.
ICD, implantable cardioverter defibrillator.
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Patients’ perceptions of deactivation
Understanding of, and feelings about, deactivation 
among patients and family members were variable. Some 
appeared very pragmatic:
You can’t fire, start a car when there’s no petrol in it, 
yeah? … it’s no good firing your starter motor, start-
ing your car, when there’s no petrol in it. (Janet, be-
reaved relative)
For these individuals, deactivation was not necessarily 
viewed negatively, it was a means of avoiding unpleasant 
and unnecessary shocks:
There are the end- of- life considerations […] I’m 
aware that, that this could happen [deactivation]. I 
think, yes, if I was seriously ill and near the end- of- 
life. I wouldn’t want the thing shocking me. (Isobel, 
post- implantation)
The knowledge that deactivation may be a possibility 
could even offer a sense of control. However, for some 
patients the idea of deactivation was of concern. The 
device could become a source of comfort, which patients 
wished to keep activated as long as possible. This was 
particularly apparent among those who had recently had 
their ICD implanted.
Burt: If you were to take it off us now I’d miss it
Interviewer: So [you] would never think of switching 
it off?
Burt: No, no, no (Burt, post- implantation)
Appropriate timing of deactivation discussions
Preimplantation
Preimplantation offers the first opportunity to introduce 
deactivation. It was recognised that discussing deactiva-
tion could influence a patient’s decision on implantation. 
A few patients indicated that, had they been aware of the 
ICD’s potential to influence their mode of death and 
the possible need for future deactivation, this may have 
affected their decision making.
If it had been mentioned, I might have well have 
thought about not having one (Adrian, post- implant)
Although most patients expressed a preference to be 
informed about deactivation prior to implantation, some 
clinicians were less convinced. They felt that discussions 
about deactivation and end- of- life, even when hypothet-
ical, conflicted with perceived patient needs and expecta-
tions of doctor–patient encounters.
I mean most patients don’t want to talk about it 
[EOL]… they come to see you ‘cause they want to get 
better. They don’t want to be told, “Well, you’re going 
to die.” (Dr B, non- implanting cardiologist)
Introducing deactivation pre- implantation was viewed 
as an ‘illogical juxtaposition’, which might give mixed 
messages and cause distress. ICDs are offered as a poten-
tially lifesaving intervention; to discuss end of life was 
seen as inappropriate and potentially confusing. Clini-
cians also expressed concerns that patients might develop 
misconceptions that deactivation would result in imme-
diate death.
I suppose also this is something to do with your 
heart and how people comprehend that, so it seems 
it can be a lot more immediate and a lot more life- 
threatening even at the end- of- life. (Dr D, palliative 
care clinician)
Questions were also raised about patients’ ability to 
remember information about deactivation given preim-
plantation. Preimplantation is often a time of high stress, 
when patients are expected to digest a considerable 
amount of information. Expecting patients to absorb 
and process information about deactivation may be 
unrealistic.
But I don’t think that people at that point [implan-
tation] can really take on board that at some distant 
point in the future that they might need it changing 
(Dr E, palliative care clinician)
Ongoing and evolving discussions
Rather than one- off conversations, both patients and clini-
cians indicated that deactivation should be an ongoing 
and evolving discussion, where the appropriateness of the 
ICD and how it fits with the patient’s life is regularly reas-
sessed. It was thought that ‘sowing the seed’ of deactiva-
tion pre- implantation might facilitate later conversations.
you have to sow the seed, you know, plant the seed 
about what might happen in the future. (Nurse C, 
heart failure nurse)
The point of referral for an ICD could be an initial 
prompt to introduce the concept of deactivation, which 
could be revisited at intervals. One participant suggested 
that ‘key points in admissions’ could be used as triggers 
for deactivation discussions. Hospital and hospice admis-
sions, and ICD firing or replacement, could be prompts 
for deactivation discussions. Inclusion of the patient on 
palliative care registers and production of ACP documen-
tation, such as a do not attempt cardiopulmonary resus-
citation form, could be used as final trigger points where 
deactivation must be discussed. This approach could 
avoid patients ‘falling through the gaps’, ensuring that 
every patient is engaged in deactivation discussions in a 
timely and appropriate manner.
Responsibility for deactivation discussions and decisions
Heart failure nurses, implanting cardiologists, physiolo-
gists, palliative care clinicians and primary care clinicians 
may all have a role in both advance deactivation discus-
sions and the ultimate decision to deactivate the ICD. 
However, no single clinical group currently took primary 
responsibility for these tasks.
Although cardiologists possess a high level of exper-
tise that may facilitate them engaging patients in these 
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discussions, their role is traditionally focused on saving 
patients.
I think doctors don’t like talking about dying, be-
cause it’s a sign, it’s a sign that you have failed (Dr F, 
implanting cardiologist)
Further, depending on the patient’s condition, contact 
with the cardiologist following implantation of the device 
may be infrequent, and so their capacity to have an 
ongoing role in deactivation discussions may be limited.
Cardiac physiologists have regular contact with ICD 
patients, offering an opportunity to engage patients 
in ongoing discussions. However, some of the physiol-
ogists interviewed appeared reticent to engage in this 
conversation.
So although I think we are in a good position in some 
ways, I think maybe there are other professionals out 
there who are in a position to do it as well. (Mr G, 
cardiac physiologist)
This reticence may be related to a feeling that they 
lacked the requisite skills to engage patients in SDM about 
continuation of ICD therapy. Cardiac physiologists’ confi-
dence and comfort with regards to these responsibilities 
may be improved by additional training. It is such a hard 
thing to do [discussing deactivation and death]. Prob-
ably need some training on how to broach the subject 
and when to broach it, and what to say. (Ms I, cardiac 
physiologist)
Heart failure nurses felt they were already undertaking 
the work of engaging patients in deactivation discussions.
I have quite a few interesting conversations about 
death when I’m talking about defibrillators … it’s just 
a simple sentence, ‘your device will be switched off at 
some point, you can’t live forever’ (Nurse H, heart 
failure nurse)
Clinicians recognised that there are various profes-
sionals who could have a role in engaging patients in 
deactivation discussions.
I think for any given patient somebody’s going to be 
taking the lead, and it’s not always clear- cut by role 
who that should be, so it may either be the GP [pri-
mary care physician], it’s conceivably a heart failure 
nurse, it’s conceivably a MacMillan [palliative care] 
nurse or our palliative care service (Dr M, palliative 
care clinician)
DISCUSSION
Our findings demonstrate that clinicians understand 
the importance of deactivation discussions with patients 
and their families, and ACP for people with ICDs. Both 
patients and clinicians recognised the need for improve-
ment; discussions about deactivation are often occurring 
late or not at all, resulting in negative impacts on patients 
and their families. We outline approaches for ensuring 
that these important and sensitive conversations take 
place ahead of time, based on extensive observations and 
semistructured interviews.
Previous work has shown that that patients report 
limited knowledge about deactivation, which is rarely 
discussed preimplantation.23 24 30 31 Yet, SDM should 
involve bidirectional knowledge transfer between the 
patient and their families, and clinicians, including elic-
itation of individual patient preferences and values for 
different outcomes.32 Indeed, informed consent requires 
that patients understand the risks, benefits and conse-
quences of interventions in the light of what is important 
to them in making such decisions.33 Our findings indi-
cate a mismatch between patients’ desire to be informed 
about deactivation and clinicians’ perception of patients’ 
information preferences, particularly pre- implantation. 
Many of our patient interviewees indicated they would 
be comfortable discussing deactivation and believed they 
should be informed about this before implantation so 
they had appropriate expectations of the future. Knowing 
about the possibility of future deactivation could afford 
patients a sense of control. However, while some clini-
cians perceived that patients did not want early deactiva-
tion discussion, and did not routinely pursue it during 
consultations, our results suggest that many patients do. 
Furthermore, the absence of such discussion may result 
in patient decisional regret and contribute to late deci-
sions about deactivation. Another potential explanation 
is that clinicians feel uncomfortable discussing death in a 
consultation that is about preventing death. Knowing that 
many patients wish to be engaged in this discussion may 
help clinicians explore this preimplantation with more 
confidence.
There is evidence that clinicians experience greater 
discomfort regarding ICD deactivation than withdrawal 
of other life sustaining therapies,34 and that ICDs are 
not considered in the same context as other end- of- life 
decisions.11 It is possible that ethical questions about 
ICD deactivation as a form of euthanasia may contribute 
to some of the unease around initiating the relevant 
discussions.9 35 Clinicians’ reluctance to engage in end- 
of- life discussions may also stem from fear and anxiety 
of accepting the limits of their ability to save patients,36 
but perversely this may contribute to denying patients the 
opportunity of ‘a good death’.
Our findings suggest a need for ongoing and evolving 
deactivation discussions, where the issue is introduced 
preimplantation (as desired by the majority of patients) 
and built on through subsequent encounters. Regularly 
revisiting ACP in relation to cardiac devices will enable 
clinicians to meet patients’ goals of care better, recog-
nising that these are likely to change over time with 
advancing years and the accumulation of health deficits.37 
However, we recognise that the increased use of remote 
device monitoring (in particular during the pandemic) 
have made this increasingly challenging. Prompts at 
appropriate points may help clinicians and patients to 
engage in these discussions,38 and there is evidence that 
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education, clinical tools and standardised electronic 
health record templates are associated with increased 
rates of ICD deactivation and clinicians’ confidence in 
managing the device.39 The possibility of empowering 
patients and families to initiate the discussion themselves 
should also be considered.
Our study demonstrates a lack of consensus among 
clinicians regarding responsibility for deactivation discus-
sions. Heart failure nurses often have established rela-
tionships and regular contact with patients and their 
families, which may facilitate them in aligning discussions 
with the patient’s values and preferences, and building 
on the discussion over time. As others,9 40 we suggest that 
a one- size- fits- all approach is not necessarily appropriate; 
the clinician most appropriate to discuss deactivation may 
differ between patients and at different times. Different 
models of care delivery for ICD patients will also have an 
influence; where specialist arrhythmia nurses are avail-
able, they will have an important role in deactivation 
discussions. However, these services were unavailable 
to the majority of our participants, resulting in more 
demand on the cardiologists and cardiac physiologists. 
Our findings support other research, which has suggested 
an interprofessional approach to initiating deactivation 
discussions.41 Whoever is involved in care must attempt to 
ensure that patients do not fall through the gaps if clini-
cians fail to engage patients proactively in these discus-
sions; and whichever clinicians are involved, they should 
have sufficient training, skills and confidence to under-
take the task. Development of clear guidelines outlining 
the responsibility of each clinician group would provide 
clarity about expectations to engage in this work, and 
should support timely discussions within the multidisci-
plinary team and between patients, clinicians and their 
families. Additionally, we recognise that specialist- led 
secondary care clinics may lack access to comprehen-
sive clinical information required for a holistic ongoing 
assessment of an individual and their circumstances. As 
such, we recognise the important role that general practi-
tioners have in ACP, and the need for further data on how 
to optimise the interface between primary and secondary 
care with regard to ICD care.
Strengths and limitations
This article is from a large qualitative study combining 
observations and interviews with a range of stakeholders. 
The observations allowed familiarity with the clinical 
setting; this also allowed us to refine our sampling strat-
egies and interview schedule for the second phase of the 
study (interviews). The range of participants sampled 
provides insight into the perspectives of various clini-
cian groups, as well as those of patients and their family 
members. However, we recognise the limitations of our 
work. Few interviews were conducted with patients with 
a deactivated ICD, or considering deactivation, because 
there is often a short time between deactivation and 
death.31 Significant attempts were made to observe clinic 
appointments where decisions about ICD deactivation 
were made, and engage these patients in interviews, but 
success in recruiting this group was limited. Recruit-
ment of bereaved relatives also proved challenging. The 
inclusion period for this group was expanded from 4 to 
6 months following bereavement to 4–18 months, which 
improved our response rate. However, some of these 
participants may have been less able to recall events 
surrounding deactivation of the ICD (or not) and death, 
given the length of time post- bereavement. Finally, 
this study did not include primary care settings; future 
research should explore the views and experiences of 
primary care clinicians regarding their role in discussions 
and decision making around ICD deactivation.
CONCLUSIONS
Our study has identified significant unmet need, partic-
ularly in the area of deactivation discussion. We believe 
that further work is needed in order to identify the 
best approach in supporting patients and clinicians to 
improving communication and care in this area. This is 
likely to include further education, development of multi-
disciplinary protocols and guidelines, and reminders for 
both clinicians and patients to have such discussions at 
key points.
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